Navigation Links
Data on DermTech's Non-invasive Test for Melanoma Are Published in the British Journal of Dermatology
Date:2/7/2011

LA JOLLA, Calif., Feb. 7, 2011 /PRNewswire/ -- DermTech International, Inc., a biotechnology company dedicated to bringing genomic medicine to dermatologists, today announced that the discovery data on its new genomic assay for melanoma have been published in the British Journal of Dermatology.  The test is based on the EGIR™ technology (Epidermal Genetic Information Retrieval) that non-invasively collects cells from the skin's surface using a custom adhesive.  Details from the paper titled "Non-invasive Genomic Detection of Melanoma" show that the test is 100% sensitive in identifying melanoma.  

The EGIR-based technology assessed pigmented skin lesions thought to be suspicious for melanoma and identified all the lesions containing either in situ (early stage) or invasive disease correctly 100% of the time.  The test registers 88% specificity (12% false positives).  These results are more accurate than any currently available melanoma detection tool.  The study was performed at 18 sites across the United States.

"Once it becomes available, this new 'tape stripping' technology will allow us to non-invasively evaluate lesions which might not rise to the level of clinical suspicion that would prompt one to perform a biopsy, but which nonetheless, might harbor melanoma," said Mitchell Kline, MD, Clinical Assistant Professor of Dermatology, New York Presbyterian-Weill Cornell Medical School.  "I believe that this genomic-based approach will allow dermatologists to more fully assess patients in advance of a biopsy and the test's very low false positive rate should translate to a reduced number of required excisions.  This is a technology I expect will have advantages for patients and the healthcare system."

The paper shows that the EGIR method, which uses adhesive to harvest cells from the skin, identified genes that were differentially expressed in melanomas versus normal skin and nevi.  Class prediction modeling identified a 17-gene biomarker that detects both in situ and invasive disease.  As part of the year-long multi-center study, 202 total lesional samples were collected (samples included superficial spreading melanoma, nodular melanoma and lentigo maligna, often misdiagnosed as solar lentigo, a sun spot).  

"Worldwide, the incidence rate of melanoma is climbing faster than any other cancer," said Daniel M. Siegel, MD, incoming President-Elect of the American Academy of Dermatology.  "Accurate detection remains the most significant challenge that dermatologists face daily in their practices.  Early detection and full excision with proper margins is the only cure for this disease and dermatologists will benefit from tools that help them identify all instances of melanoma.  The EGIR technology in development appears to be a major step in this direction."

The current standard of care, an invasive biopsy followed by histopathologic evaluation, typically reveals the presence of melanoma just 3.5-5% of the time.  The marked increase in specificity of the genomic test may better identify which of the patient's lesions contain melanoma, effectively helping to direct biopsies.  

Many experts believe that, in addition to limiting invasive procedures, the genomic test may be more accurate than today's detection methods. In one case, as reported in the paper, a lesion that was read to be benign by standard review of histopathology was called positive for melanoma using the biomarker-based test.  The patient's tissue was then serial sectioned and re-examined by the pathologists, at which time invasive melanoma was diagnosed.

DermTech is now translating these discovery data onto a quantitative PCR platform. Preliminary results suggest the feasibility of using this 17-gene biomarker in a clinical laboratory setting.  Additional sample collection activities are ongoing in the US, Australia and Europe.

"If these findings are confirmed in an expanded clinical validation study, it would establish the EGIR-based assay as a more accurate and cost effective alternative to the currently available tools for melanoma detection," said George Schwartz, CEO, DermTech.

About DermTech International, Inc.:Headquartered in La Jolla, California, DermTech is focused on the development of the company's patented Epidermal Genetic Information Retrieval (EGIR™) technology.  The EGIR technology uses a custom adhesive tape to non-invasively and easily collect cells from the stratum corneum, i.e., the upper layer of the skin.  Genetic material (RNA) from these cells is then isolated, amplified and analyzed using molecular biology tools to determine genetic profiles to be used for a range of applications including: the non-invasive, early detection of disease, pharmaceutical R&D and theranostics.  DermTech is actively pursuing research using the EGIR technology in the areas of melanoma, prostate cancer and a number of skin conditions.  For additional information visit: www.dermtech.com.

About Melanoma: Since 1930, there has been a 2000 times increase in the lifetime risk of developing melanoma.  By 2010, current estimates indicate that 1 out of 50 people will be diagnosed with melanoma during their lifetime.(1)   Melanoma is the most common cancer in women aged 25-29.  5% to 10% of cases of cutaneous melanoma are the result of hereditary genetics in first-degree relatives.(2)   Unlike most other cancers, melanoma only infrequently responds to treatment and those that are available are highly toxic and impact quality of life.(3)   If melanoma is treated before it spreads, it is 99% curable.(4)   The ten-year survival rate for melanoma patients whose disease is detected and treated at the earliest stages is 95-99% but  drops to less then 5% for a Stage 4 melanoma (invasive).(5)     (1) CA Cancer J Clin 2008   (2) Karolinska Institute, Aug 2008   (3) NCI Melanoma Treatment Options   (4) AAD Fact Sheet 2007   (5) American Joint Committee on Cancer – AJCC.For broadcast media go to:  www.newsinfusion.com/events/dermtech

Contacts:DermTechGeorge Schwartz, CEO858.450.4222Jennifer Larson415.725.2017jlarson@dermtech.com
'/>"/>

SOURCE DermTech International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
2. UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting
3. Novel Photoconductive Life Science Research Innovation Enables Rapid, Reproducible, and Non-Invasive Cellular Excitation
4. CRi Oosight(TM) Instrument Crucial in IVF Breakthrough Demonstrating a Correlation Between Non-Invasive Egg Metrics and Pregnancy
5. Elbit Imaging Announces InSightecs First Non-Invasive Technology for Treatment of Uterine Fibroids Awarded MHLW Approval in Japan
6. First Non-Invasive Technology for Treatment of Uterine Fibroids Awarded MHLW Approval in Japan
7. Clarient, BioView Initiate Alliance to Finalize Development and Commercialize Non-Invasive Molecular Diagnostic Test for Early Detection of Lung Cancer
8. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
9. Say Goodbye to Unwanted Love Handles: CoolSculpting by ZELTIQ™ Receives FDA Clearance for Patented, Non-Invasive Cooling Treatment for Fat Reduction
10. BugLab Launches Worlds First Handheld Non-invasive Optical Density Sensor
11. iLeverage Announces the Successful Sale of the BICO Patent Portfolio for Near-Infrared Non-Invasive Blood Analytes Measurement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 ... ... Company, Cal Dining at the University of California Berkeley, and other leading institutions ... leverages the buying power of institutions to change the way animals are raised ...
Breaking Medicine News(10 mins):